New Molecular Driver of Atherosclerosis Identified: PLCE1 Pushes Artery Disease Forward

Atherosclerosis, the slow and silent thickening of artery walls that underlies most heart attacks and strokes, has long been understood as a disease of cholesterol accumulation and chronic inflammation. Yet the precise molecular switches that tip arteries from a stable, manageable state into a progressive, rupture-prone one remain incompletely mapped. A new study published in Cell Death Discovery has now identified a surprising and potentially druggable culprit: phospholipase C epsilon 1, better known as PLCE1. According to the research, PLCE1 actively exacerbates atherosclerosis by simultaneously damaging the delicate inner lining of blood vessels and fanning the inflammatory fires inside macrophages, the immune cells that patrol artery walls. Crucially, the study points to the well-known signaling protein CTNNB1, the gene that encodes beta-catenin, as the downstream target through which PLCE1 exerts much of its destructive influence.

The significance of the finding lies in its dual mechanism. Cardiovascular researchers have traditionally treated endothelial dysfunction and macrophage-driven inflammation as related but distinct strands of the atherosclerosis story. The endothelium, a single-cell-thick lining that governs vascular tone, barrier integrity, and leukocyte trafficking, is often the first casualty of cardiovascular risk factors such as hypertension, hyperlipidemia, and diabetes. When endothelial cells malfunction, they express fewer protective molecules such as nitric oxide and more adhesion molecules that invite circulating monocytes to breach the vessel wall. Meanwhile, once inside the intima, monocytes differentiate into macrophages that gorge on oxidized lipids, transform into foam cells, and release a cascade of inflammatory cytokines that amplify lesion growth. The new work suggests that PLCE1 is a single upstream node that helps orchestrate both of these pathological processes at once.

PLCE1 encodes an enzyme belonging to the phospholipase C family, proteins that cleave the membrane phospholipid PIP2 into two potent second messengers, inositol trisphosphate and diacylglycerol. These messengers mobilize intracellular calcium and activate protein kinase C, triggering a wide range of cellular responses. PLCE1 is unusual among phospholipases because it also carries a Ras-associating domain and a Ras-GEF domain, linking it directly to small GTPase signaling pathways that control cell proliferation, migration, and survival. Genetic studies over the past decade and a half have repeatedly flagged variants within the PLCE1 gene locus in genome-wide association studies of coronary artery disease, and even earlier of stroke risk in some populations. What those association studies could not resolve was whether PLCE1 is merely a bystander genetically linked to true disease drivers, or an active participant in the disease process. The new findings argue firmly for the latter.

Using a combination of cellular models, animal experiments, and mechanistic analyses, the research team demonstrated that elevated PLCE1 activity worsens endothelial dysfunction. In endothelial cells, increased PLCE1 expression was associated with impaired endothelial function markers, disturbed barrier behavior, and a shift toward the pro-inflammatory, pro-adhesive state that characterizes early lesion formation. When the investigators suppressed PLCE1 in experimental models of atherosclerosis, the resulting lesions were less severe, and the endothelial lining displayed healthier functional characteristics. This directional evidence, that manipulation of PLCE1 changes disease severity rather than simply tracking with it, is the kind of causal data that genetic association studies alone can never provide.

The second arm of the mechanism concerns macrophages, the immune workhorses whose transformation into lipid-laden foam cells defines the atherosclerotic plaque. The study found that PLCE1 promotes a pro-inflammatory phenotype in macrophages, driving the production and release of inflammatory mediators that recruit further immune cells and destabilize plaques. Macrophage inflammation is now recognized as a central engine of atherosclerotic progression, a view powerfully validated by the landmark CANTOS clinical trial, which showed that directly targeting the inflammatory cytokine IL-1 beta reduces cardiovascular events independently of cholesterol lowering. By implicating PLCE1 upstream of macrophage inflammatory activation, the new research adds a candidate control point that could, in principle, restrain this inflammatory engine at its source.

The most consequential discovery, however, may be the identification of CTNNB1 as the molecular target linking PLCE1 to both pathologies. CTNNB1 encodes beta-catenin, the central transducer of the canonical Wnt signaling pathway and a transcriptional co-regulator with its finger in countless developmental and inflammatory processes. In the study’s experimental framework, PLCE1 was shown to act on beta-catenin signaling, and beta-catenin in turn mediated the downstream effects on endothelial cells and macrophages. When beta-catenin was experimentally depleted, the harmful consequences of PLCE1 overexpression were blunted. This epistatic relationship, in which removing the target abolishes the effect of the driver, is a classic hallmark of a genuine signaling axis, and it suggests a linear pathway: PLCE1 acts upon beta-catenin, and beta-catenin drives the gene expression programs that produce endothelial dysfunction and macrophage inflammation.

This proposed axis is biologically plausible in light of prior literature. Beta-catenin signaling has been repeatedly implicated in vascular inflammation, with Wnt-beta-catenin activity reported to increase endothelial permeability and to promote inflammatory gene expression in both endothelial cells and macrophages under atherosclerotic conditions. What the new study contributes is the placement of PLCE1 upstream of this pathway in the specific context of arterial disease, transforming scattered mechanistic hints into a coherent, testable model. It also offers a potential explanation for longstanding genetic associations between PLCE1 variants and cardiovascular outcomes: those variants may alter the intensity of beta-catenin signaling in the vessel wall, tuning the inflammatory set point of atherosclerotic tissue.

From a therapeutic standpoint, the findings are provocative but must be tempered by important caveats. Both PLCE1 and beta-catenin are pleiotropic molecules, meaning they perform essential functions far beyond the vascular system. Beta-catenin, in particular, is indispensable for stem cell maintenance in the intestine, bone formation, and a host of developmental processes, which is why systemic Wnt-pathway inhibitors have repeatedly stumbled in cancer trials due to toxicity. Any attempt to translate the PLCE1-beta-catenin axis into a cardiovascular therapy would almost certainly require highly targeted delivery, perhaps to vascular endothelium or lesional macrophages, or the identification of downstream effectors that are more vascular-specific. The study does not itself report a candidate drug or clinical intervention, and its conclusions rest on experimental models whose fidelity to human atherosclerosis, while substantial, is never complete.

Nevertheless, the work exemplifies a broader and encouraging trend in cardiovascular biology: the convergence of human genetics, molecular signaling, and immunology into unified mechanistic accounts of atherosclerosis. For decades, the field’s therapeutic triumphs came almost exclusively from lipid metabolism, embodied by statins and more recently PCSK9 inhibitors. Yet a large residual risk persists in patients whose cholesterol is well controlled, and that residual burden is increasingly attributed to inflammation and vascular dysfunction. Identifying molecules like PLCE1 that couple inflammatory and endothelial pathologies through a defined signaling route gives researchers exactly the kind of targets needed to address this residual risk. It also enriches the interpretation of existing genetic risk scores, which currently aggregate thousands of variants of unknown function. Each variant that is functionally resolved, as PLCE1 variants now partly are, converts statistical prediction into biological insight.

For now, the immediate value of the study lies in its demonstration of a principle: that a single enzyme can coordinate two of the most destructive processes in atherosclerosis through a well-defined molecular partner. Future work will need to confirm the PLCE1-beta-catenin axis in human tissue, map precisely how PLCE1 activity modifies beta-catenin at the molecular level, and determine whether existing or novel pharmacological tools can safely modulate this pathway in patients at risk. If those steps succeed, a gene discovered through population association studies may finally graduate from statistical curiosity to therapeutic target, offering a new angle of attack on the world’s leading cause of death. In a disease as complex and multifactorial as atherosclerosis, every newly charted junction in the signaling map is a potential checkpoint at which progression might be halted, and PLCE1 has just been added to that map in bold.

Subject of Research: The role of PLCE1 in driving atherosclerosis through endothelial dysfunction and macrophage inflammation via CTNNB1

Article Title: PLCE1 exacerbates the development of atherosclerosis by driving endothelial dysfunction and macrophage inflammation via targeting CTNNB1

Article References: Cheng, W.-L., Shi, Y., Zhang, Q., Cai, Z., Jiang, F.-X., Kong, X., Cao, J.-L., Peng, L., Chen, M., He, T., & Wang, H. (2026). PLCE1 exacerbates the development of atherosclerosis by driving endothelial dysfunction and macrophage inflammation via targeting CTNNB1. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03309-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03309-2

Keywords: PLCE1, atherosclerosis, CTNNB1, beta-catenin, endothelial dysfunction, macrophage inflammation, cardiovascular disease, Cell Death Discovery, Wnt signaling, foam cells, heart disease, molecular mechanism